AP
CABA icon

Antipodes Partners’s Cabaletta Bio CABA Stock Holding History

Antipodes Partners’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,616
Closed -$15.1K – 134
2026
Q1 		$15.1K Sell
5,616
-11,571
-67% -$32.1K ﹤0.01% 124
2025
Q4 		$37.6K Buy
+17,187
New +$42.6K ﹤0.01% 113

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Antipodes Partners's CABA Position: Q2 2026 in Review

Antipodes Partners sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 5,616 shares — an estimated $15.1K sold.

Antipodes Partners first reported a position in CABA in Q4 2025 and held it in 2 quarters. The position peaked at $37.6K in Q4 2025. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Antipodes Partners reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 5,616 Cabaletta Bio shares in Q2 2026, an estimated $15.1K.
  • Antipodes Partners first reported a position in Cabaletta Bio in Q4 2025 and held it in 2 quarters.
  • Antipodes Partners's Cabaletta Bio position peaked at $37.6K in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.